Nuventra is pleased to announce the addition of two experienced scientists, Chuck Poole, B.S. and Howard A. Ball, Ph.D., to its growing team of senior consultants. Both bring more than 25 years of nonclinical and clinical pharmacology knowledge and experience. Chuck Poole joins Nuventra as Director of Nonclinical and Clinical Pharmacology and Howard A. Ball as a Senior Consultant, Clinical Pharmacology and Pharmacokinetics.
“Mr. Poole and Dr. Ball bring more nonclinical and clinical pharmacology expertise to Nuventra’s team,” said Geoffrey Banks, Ph.D., Nuventra’s CEO, adding further, “We are excited to welcome them to our growing team of drug development experts.”
Chuck Poole, B.S.
Mr. Poole is a DMPK scientist with over 20 years of large pharma experience in preclinical study design and dose prediction for First-Time-In-Human studies. As a DMPK scientist, he has technical expertise in ADME, pharmacokinetics, mass spectrometry, and bioanalysis in support of IND fillings, and dose selection. In the past he managed a team of 5 scientists providing preclinical bioanalytical and ADME program support.
Howard A. Ball, Ph.D.
Dr. Ball is a Senior Pharmacologist, having been in the drug development industry since 1989, with broad experience in leading cross-functional project teams such as preclinical pharmacology, pharmacokinetics, DMPK, safety, and toxicology for early compound selection and due-diligence activities, through Clinical Pharmacology support for Phases I-III and BLA/NDA submission. His therapeutic areas of expertise include oncology, cardiovascular and respiratory drug development.